XML 59 R47.htm IDEA: XBRL DOCUMENT v3.22.4
Organization and Summary of Significant Accounting Policies - Revenue by Geographical Region (Details) - USD ($)
$ in Millions
 6 Months Ended 12 Months Ended
Dec. 31, 2020
Dec. 31, 2022
Dec. 31, 2021
Jun. 30, 2020
Disaggregation of Revenue [Line Items]        
Total revenue $ 299.8 $ 678.4 $ 690.6 $ 638.6
Testing revenue        
Disaggregation of Revenue [Line Items]        
Total revenue 279.6 678.4 666.4 586.9
Hereditary Cancer        
Disaggregation of Revenue [Line Items]        
Total revenue 159.3 305.5 316.3 347.4
Tumor Profiling        
Disaggregation of Revenue [Line Items]        
Total revenue 33.9 128.6 120.9 48.3
Prenatal        
Disaggregation of Revenue [Line Items]        
Total revenue 37.6 116.4 106.8 76.7
Pharmacogenomics        
Disaggregation of Revenue [Line Items]        
Total revenue 29.8 127.6 93.7 74.1
Autoimmune        
Disaggregation of Revenue [Line Items]        
Total revenue 18.0 0.3 28.2 39.1
Other        
Disaggregation of Revenue [Line Items]        
Total revenue 1.0 0.0 0.5 1.3
Other revenue        
Disaggregation of Revenue [Line Items]        
Total revenue 20.2 0.0 24.2 51.7
United States        
Disaggregation of Revenue [Line Items]        
Total revenue 275.4 591.5 603.7 596.2
United States | Testing revenue        
Disaggregation of Revenue [Line Items]        
Total revenue 255.3 591.5 579.5 559.8
United States | Hereditary Cancer        
Disaggregation of Revenue [Line Items]        
Total revenue 140.9 263.5 271.0 329.8
United States | Tumor Profiling        
Disaggregation of Revenue [Line Items]        
Total revenue 28.2 84.5 80.4 39.2
United States | Prenatal        
Disaggregation of Revenue [Line Items]        
Total revenue 37.4 115.6 106.2 76.4
United States | Pharmacogenomics        
Disaggregation of Revenue [Line Items]        
Total revenue 29.8 127.6 93.7 74.1
United States | Autoimmune        
Disaggregation of Revenue [Line Items]        
Total revenue 18.0 0.3 28.2 39.1
United States | Other        
Disaggregation of Revenue [Line Items]        
Total revenue 1.0 0.0 0.0 1.2
United States | Other revenue        
Disaggregation of Revenue [Line Items]        
Total revenue 20.1 0.0 24.2 36.4
Rest of world        
Disaggregation of Revenue [Line Items]        
Total revenue 24.4 86.9 86.9 42.4
Rest of world | Testing revenue        
Disaggregation of Revenue [Line Items]        
Total revenue 24.3 86.9 86.9 27.1
Rest of world | Hereditary Cancer        
Disaggregation of Revenue [Line Items]        
Total revenue 18.4 42.0 45.3 17.6
Rest of world | Tumor Profiling        
Disaggregation of Revenue [Line Items]        
Total revenue 5.7 44.1 40.5 9.1
Rest of world | Prenatal        
Disaggregation of Revenue [Line Items]        
Total revenue 0.2 0.8 0.6 0.3
Rest of world | Pharmacogenomics        
Disaggregation of Revenue [Line Items]        
Total revenue 0.0 0.0 0.0 0.0
Rest of world | Autoimmune        
Disaggregation of Revenue [Line Items]        
Total revenue 0.0 0.0 0.0 0.0
Rest of world | Other        
Disaggregation of Revenue [Line Items]        
Total revenue 0.0 0.0 0.5 0.1
Rest of world | Other revenue        
Disaggregation of Revenue [Line Items]        
Total revenue $ 0.1 $ 0.0 $ 0.0 $ 15.3